Literature DB >> 33653774

Hepatitis B-Induced IL8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation.

Changlu Zhang1,2, Yanan Gao2, Chengzhi Du2,3, Geoffrey J Markowitz4, Jing Fu5, Zhenxing Zhang2, Chunliang Liu5, Wenhao Qin5, Hongyang Wang5, Fan Wang6,7, Pengyuan Yang8,2.   

Abstract

Hepatitis B-associated hepatocellular carcinoma (HCC) is often accompanied by severe vascular invasion and portal vein tumor thrombus, leading to a poor prognosis. However, the underlying mechanism of this disease remains obscure. In this study, we demonstrate that the hepatitis B virus (HBV)-encoded gene HBx induces high IL8 production through MEK-ERK signal activation, leading to enhanced endothelial permeability to facilitate tumor vascular invasion. In a vascular metastatic model using a tail vein injection in a transgenic mouse with selective expression of human CXCR1 in the endothelium, activation of the IL8-CXCR1 cascade by overexpression of IL8 in tumor cells dramatically enhanced liver metastasis. Mechanistically, IL8 selectively induced GARP-latent-TGFβ in liver sinusoidal endothelial cells and subsequently provoked preferential regulatory T-cell polarization to suppress antitumor immunity. Collectively, these findings reveal a hepatitis B-associated IL8-CXCR1 signaling axis that mediates vascular invasion and local microenvironmental immune escape of HCC to induce intrahepatic metastasis, which may serve as potential therapeutic targets for HBV-associated HCC. SIGNIFICANCE: This study identifies a hepatitis B-induced IL8/CXCR1/TGFβ signaling cascade that suppresses antitumor immunity and enhances metastasis in hepatocellular carcinoma, providing new potential targets for therapeutic intervention. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33653774     DOI: 10.1158/0008-5472.CAN-20-3453

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Cytokines and Chemokines in HBV Infection.

Authors:  Shihong Zhong; Tianling Zhang; Libo Tang; Yongyin Li
Journal:  Front Mol Biosci       Date:  2021-12-02

Review 2.  Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection.

Authors:  Yan Yan; Yuanwang Qiu; Chantsalmaa Davgadorj; Chunfu Zheng
Journal:  Front Cell Infect Microbiol       Date:  2022-02-18       Impact factor: 5.293

3.  The Genetic Profile and Serum Level of IL-8 Are Associated with Chronic Hepatitis B and C Virus Infection.

Authors:  Ednelza da Silva Graça Amoras; William Botelho de Brito; Maria Alice Freitas Queiroz; Simone Regina Souza da Silva Conde; Izaura Maria Vieira Cayres Vallinoto; Ricardo Ishak; Antonio Carlos Rosário Vallinoto
Journal:  Biomolecules       Date:  2021-11-10

Review 4.  Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy.

Authors:  Chun-Ye Zhang; Shuai Liu; Ming Yang
Journal:  World J Gastroenterol       Date:  2022-07-21       Impact factor: 5.374

5.  Construction and validation of a prognostic model with RNA binding protein-related mRNAs for the HBV-related hepatocellular carcinoma patients.

Authors:  Shaohua Xu; Hui Liu; Renyun Tian; Jiahui Xie; Su Chen; Junyun Luo; Haizhen Zhu; Yirong Wang; Zhaoyong Li
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.

Authors:  Genhao Zhang
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

7.  Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma.

Authors:  Xiang Wang; Chunliang Liu; Jianan Chen; Lei Chen; Xianwen Ren; Minghui Hou; Xiuliang Cui; Youhai Jiang; Erdong Liu; Yali Zong; Anqi Duan; Xiaohui Fu; Wenlong Yu; Xiaofang Zhao; Zhao Yang; Yongjie Zhang; Jing Fu; Hongyang Wang
Journal:  Cell Discov       Date:  2022-10-05       Impact factor: 38.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.